Halozyme Therapeutics, Inc. (HALO)
$
62.13
+0.50 (0.80%)
Key metrics
Financial statements
Free cash flow per share
5.4778
Market cap
7.3 Billion
Price to sales ratio
5.2079
Debt to equity
0
Current ratio
4.6598
Income quality
2.0561
Average inventory
181.1 Million
ROE
0.9267
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally, focusing on advancing drug delivery technologies. The company recorded an operating income of $816,293,000.00 reflecting its earnings from core operations, while incurring an interest expense of $18,126,000.00 indicative of its debt servicing obligations. The total costs and expenses for the company are $580,318,000.00 highlighting its overall spending. Additionally, the diluted EPS is $2.56 accounting for potential share dilution, and the company incurred an income tax expense of $149,986,000.00 indicating its tax obligations. Its flagship product, Hylenex recombinant, utilizes patented recombinant human hyaluronidase enzyme (rHuPH20) to facilitate subcutaneous fluid administration, enhancing the dispersion and absorption of other injected drugs. The company develops several important therapeutics including Perjeta, RITUXAN HYCELA, and MabThera SC for non-Hodgkin lymphoma, as well as HYQVIA for immunodeficiency disorders. Furthermore, collaborations with several renowned organizations support its innovative efforts in treating various conditions. The stock is affordable at $77.81 suitable for budget-conscious investors, which, combined with a high average trading volume of 1,859,142.00 indicates strong liquidity. With a mid-range market capitalization of $7,332,396,210.00 the company is a steady performer in the competitive landscape of the Biotechnology industry. As a key player in this sector, it significantly contributes to the overall market landscape, driving innovation and growth. In addition to its successful products, the company is actively developing treatments such as Tecentriq for non-small cell lung cancer and OCREVUS for multiple sclerosis, alongside other promising therapies aimed at a variety of serious health conditions. Halozyme's extensive collaborations with top pharmaceutical companies also underscore its commitment to addressing unmet medical needs and advancing healthcare outcomes globally.
Is Halozyme Therapeutics, Inc. (HALO) a good investment?
Investing in Halozyme Therapeutics, Inc. (HALO) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bearish outlook. Always conduct your own research before investing.
What is Halozyme Therapeutics, Inc. (HALO)'s stock forecast?
Analysts predict Halozyme Therapeutics, Inc. stock to fluctuate between $47.50 (low) and $82.22 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Halozyme Therapeutics, Inc.'s market capitalization?
As of 2026-03-30, Halozyme Therapeutics, Inc.'s market cap is $7,332,396,210, based on 118,017,000 outstanding shares.
How does Halozyme Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Halozyme Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Halozyme Therapeutics, Inc. (HALO) stock?
To buy Halozyme Therapeutics, Inc. (HALO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for HALO. Place an order (Market, Limit, etc.).
What is the best time to invest in Halozyme Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Halozyme Therapeutics, Inc. perform in the last earnings report?
Revenue: $1,396,611,000 | EPS: $2.64 | Growth: -24.57%.
Where can I find Halozyme Therapeutics, Inc.'s investor relations reports?
Visit https://www.halozyme.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Halozyme Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Halozyme Therapeutics, Inc. stock?
All-time high: $82.22 (2026-02-09) | All-time low: $29.85 (2023-05-09).
What are the key trends affecting Halozyme Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
etftrends.com
The latest buzz acronym in the investment community, spurred in part by the artificial intelligence (AI) trade, is HALO, or “heavy assets, low obsolescence.” The catchy acronym is relevant to dividend investors because many of the companies in the hard assets realm are dividend payers.
prnewswire.com
SAN DIEGO, March 12, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced that David Ramsay has been appointed Interim Chief Financial Officer (CFO), effective March 23, 2026. Mr. Ramsay will oversee all financial operations while the company continues its active search for a permanent CFO.
seekingalpha.com
Halozyme Therapeutics, Inc. (HALO) Presents at The Citizens Life Sciences Conference 2026 Transcript
seekingalpha.com
Halozyme Therapeutics, Inc. (HALO) Presents at Leerink Global Healthcare Conference 2026 Transcript
seekingalpha.com
Halozyme Therapeutics, Inc. (HALO) Presents at TD Cowen 46th Annual Health Care Conference Transcript
prnewswire.com
SAN DIEGO, Feb. 25, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, is scheduled to present and host investor meetings at the following investor conferences: Event: TD Cowen 46th Annual Healthcare Conference Format: Fireside Chat and 1x1 Meetings Presentation Date: Tuesday, March 3, 2026 Presentation Time: 8:10am PT / 11:10am ET Location: Boston, MA Event: Leerink Partners Global Healthcare Conference Format: Fireside Chat and 1x1 Meetings Presentation Date: Tuesday, March 10, 2026 Presentation Time: 10:00am PT / 1:00pm ET Location: Event: Format: Presentation Date: Presentation Time: Location: Miami, FL The Citizens Life Sciences Conference Fireside Chat and 1x1 Meetings Wednesday, March 11, 2026 8:20am PT / 11:20am ET Miami, FL Live audio webcasts of the presentations will be available in the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference.
zacks.com
ASTS lands a $30 million Space Development Agency contract to deploy BlueBird LEO satellites, advancing direct-to-device defense communications.
businesswire.com
MIDLAND, Texas--(BUSINESS WIRE)---- $ASTS #AST--AST SpaceMobile, Inc. (“AST SpaceMobile”) (NASDAQ: ASTS), the company building the first and only space-based cellular broadband network accessible directly by everyday smartphones, designed for both commercial and government applications, today announced that it has entered into an agreement with the United States Space Development Agency (SDA) for the Europa Track 2 Commercial Solutions program. The agreement, executed under the Hybrid Acquisition for prolifer.
zacks.com
HALO swings to Q4 loss on acquisition charge, but revenues surge 52%, fueled by royalties and product sales and top estimates.
See all news
